BSA
CORT icon

Braun Stacey Associates’s Corcept Therapeutics CORT Stock Holding History

Braun Stacey Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-264,297
Closed -$9.2M – 113
2025
Q4 		$9.2M Sell
264,297
-16,367
-6% -$1.29M 0.3% 85
2025
Q3 		$23.3M Sell
280,664
-6,590
-2% -$477K 0.76% 57
2025
Q2 		$21.1M Sell
287,254
-79,365
-22% -$5.75M 0.76% 60
2025
Q1 		$41.9M Buy
366,619
+70,229
+24% +$4.27M 1.71% 10
2024
Q4 		$14.9M Buy
+296,390
New +$15.5M 0.56% 72

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Braun Stacey Associates's CORT Position: Q1 2026 in Review

Braun Stacey Associates sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 264,297 shares — an estimated $9.2M sold.

Braun Stacey Associates first reported a position in CORT in Q4 2024 and held it in 5 quarters. The position peaked at $41.9M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Braun Stacey Associates reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Braun Stacey Associates sold 264,297 Corcept Therapeutics shares in Q1 2026, an estimated $9.2M.
  • Braun Stacey Associates first reported a position in Corcept Therapeutics in Q4 2024 and held it in 5 quarters.
  • Braun Stacey Associates's Corcept Therapeutics position peaked at $41.9M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Braun Stacey Associates's 13F filing for Q1 2026, filed 22 Apr 2026.